XTX Topco Ltd Makes New Investment in Pacira BioSciences, Inc. (NASDAQ:PCRX)

XTX Topco Ltd acquired a new position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 27,738 shares of the company's stock, valued at approximately $523,000. XTX Topco Ltd owned about 0.06% of Pacira BioSciences at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in PCRX. Barclays PLC lifted its holdings in shares of Pacira BioSciences by 4.4% during the 4th quarter. Barclays PLC now owns 423,221 shares of the company's stock worth $7,972,000 after acquiring an additional 17,744 shares during the period. Sterling Capital Management LLC increased its holdings in shares of Pacira BioSciences by 779.4% in the fourth quarter. Sterling Capital Management LLC now owns 1,363 shares of the company's stock valued at $26,000 after purchasing an additional 1,208 shares in the last quarter. Capital Fund Management S.A. raised its holdings in Pacira BioSciences by 34.6% during the 4th quarter. Capital Fund Management S.A. now owns 175,225 shares of the company's stock worth $3,301,000 after purchasing an additional 45,016 shares during the last quarter. Raymond James Financial Inc. acquired a new position in Pacira BioSciences in the fourth quarter valued at approximately $190,000. Finally, Renaissance Technologies LLC boosted its position in shares of Pacira BioSciences by 0.7% in the 4th quarter. Renaissance Technologies LLC now owns 1,992,601 shares of the company's stock worth $37,541,000 after purchasing an additional 13,604 shares during the last quarter. Institutional investors own 99.73% of the company's stock.

Pacira BioSciences Stock Down 0.3 %

PCRX traded down $0.07 during trading hours on Friday, hitting $25.93. 123,111 shares of the company's stock were exchanged, compared to its average volume of 974,091. The stock's 50-day moving average is $24.51 and its two-hundred day moving average is $21.38. Pacira BioSciences, Inc. has a 1-year low of $11.16 and a 1-year high of $31.67. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51. The stock has a market cap of $1.20 billion, a price-to-earnings ratio of -12.76 and a beta of 0.71.

Analyst Ratings Changes

Several research analysts recently weighed in on PCRX shares. Needham & Company LLC reissued a "buy" rating and set a $32.00 price objective on shares of Pacira BioSciences in a research note on Tuesday, April 8th. Truist Financial raised shares of Pacira BioSciences from a "sell" rating to a "hold" rating and boosted their price target for the company from $8.00 to $25.00 in a report on Thursday, January 30th. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $18.00 price target on shares of Pacira BioSciences in a research report on Tuesday, January 14th. HC Wainwright boosted their price objective on Pacira BioSciences from $48.00 to $65.00 and gave the company a "buy" rating in a research report on Tuesday, April 8th. Finally, Barclays raised their target price on shares of Pacira BioSciences from $17.00 to $24.00 and gave the stock an "overweight" rating in a report on Friday, February 28th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $26.67.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.